Role of multidrug resistance protein 2 (MRP2) in chemoresistance and clinical outcome in oesophageal squamous cell carcinoma

摘要: Although multidrug resistance protein 2 (MRP2) confers chemoresistance in some cancer types, its implication on oesophageal squamous cell carcinoma (ESCC) remains unclear. We evaluated MRP2 expression by immunohistochemistry and RT–PCR using 81 resected specimens from ESCC patients who did or not receive neo-adjuvant chemotherapy (NACT), including 5-fluorouracil, doxorubicin, cisplatin (CDDP). Correlation between response to was also examined 42 pre-therapeutic biopsy samples eight lines. MRP2-positive immunostaining more frequently observed ESCCs with NACT than those without (27.3 vs 5.4%). The showed poorer prognosis MRP2-negative (5-year survival rate, 25.6 55.7%). Concordantly, 2.1-fold higher mRNA of (P=0.0350). In NACT, non-responders 2.9-fold responders (P=0.0035). Among the panel lines, TE14 highest along strongest CDDP. Inhibition small-interfering RNA reduced Our data suggested that is one molecules, which regulate sensitivity CDDP advanced patients.